Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): Regulation by IGFBP-5-(201-218)

American Journal of Physiology - Endocrinology and Metabolism

Volumn 273, Issue 5 36-5, 1997, Pages

  Campbell, Phil G ^a   Andress, Dennis L ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Hydroxyapatite; Insulin like growth factor bioavailability; Osteoblast physiology

Indexed keywords

HEPARIN BINDING PROTEIN; PLASMIN; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 5; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; HORMONE PROTEIN COMPLEX; HUMAN; HUMAN CELL; INHIBITION KINETICS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN;

EID: 0030657905     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.273.5.e996     Document Type: Article

References (17)

1. Andress, D. L. Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J. Biol. Chem. 270: 28289-28296, 1995.
2. Andress, D. L., and R. S. Birnbaum. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267: 11467-11472, 1992.
3. Andress, D. L., S. M. Loop, J. Zapf, and M. C. Kiefer. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem. Biophys. Res. Commun. 195: 25-30, 1993.
4. Arai, T., A. Arai, W. H. Busby, and D. R. Clemmons. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 135: 2358-2363, 1994.
5. Arai, T., J. Clarke, A. Parker, W. Busby, Jr., T. Nam, and D. R. Clemmons. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I in response to heparin. J. Biol. Chem. 271: 6099-6106, 1996.
6. Bautista, C. M., D. L. Baylink, and S. Mohan. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem. Biophys. Res. Commun. 176: 756-763, 1991.
7. Booth, B. A., M. Boes, D. L Andress, B. L. Dake, M. C. Kiefer, C. Maack, R. J Linhardt, K. Bar, E. E. O. Caldwell, J. Weiler, and R. S. Bar. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. 5: 1-7, 1995.
8. Campbell, P. G. Localization of the insulin-like growth factor (IGF) and plasmin systems in osteosarcoma cells: mechanism for the utilization of bone matrix IGFs (Abstract). Mol. Biol. Cell. 4: S1694, 1993.
9. 8a. Campbell, P. G., and D. L. Andress. Insulin-like growth factor (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding. Am. J. Physiol. 273 (Endocrinol. Metab. 36): E1005-E1013, 1997.
10. Campbell, P. G., and J. F. Novak. Insulin-like growth factor binding protein (IGFBP) inhibits IGF action on human osteosarcoma cells. J. Cell. Physiol. 149: 293-300, 1991.
11. Campbell, P. G., J. F. Novak, K. Wines, and P. E. Walton. Localization of plasmin activity on osteosarcoma cells: cell surface proteolysis of insulin-like growth factor binding proteins. Growth Regul. 3: 95-98, 1993.
12. Campbell, P. G., J. F. Novak, T. B. Yanosick, and J. H. McMaster. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412, 1992.
13. Campbell, P. G., K. Wines, T. B. Yanosick, and J. F. Novak. Binding and activation of plasminogen on the surface of osteosarcoma cells. J. Cell. Physiol. 159: 1-10, 1994.
14. Campbell, P. G., T. B. Yanosick, and J. F. Novak. Plasmin activatable growth factors differentially regulate secretion of plasmin system components by osteosarcoma cells (Abstract). J. Bone Min. Res. 7, S480, 1992.
15. Fowlkes, J. L., D. M. Serra, C. K. Rosenberg, and K. M. Thrailkill. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J. Biol. Chem. 270: 27481-27488, 1995.
16. Guler, H. P., J. Zapf, C. Schmid, and E. R. Froesch. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol. Copenhagen 121: 753-758, 1989.
17. Hodgkinson, S. C., J. R. Napier, G. S. G. Spencer, and J. J. Bass. Glycosaminoglycan binding characteristics for the insulin-like growth factor-binding proteins. J. Mol. Endocrinol. 123: 105-112, 1994.